Bridging Innovative RNA Biology and Drug Discovery
Our mission:
By combining multidisciplinary academic innovators with biotech-inspired objectives and focus, our goal is to uncover novel disease solutions by advancing the science of RNA regulation, developing new technological platforms, and discovering early-stage therapeutics.
Our Approach:
Recruit and nucleate current and next generation leaders in RNA biology and cultivate environment of collaboration, technology innovation and entrepreneurship
Build multi-disciplinary drug discovery teams focused on translating transformative RNA discoveries into therapeutics utilizing biotech best practices
Integrate academic innovators with therapeutic teams to bridge the gap between discovery and clinically applicable therapies
CENTER Happenings
recent media & publications
Dr. Furqan Fazal and collaborator Dr. Gloria Echeverria were awarded a pilot grant from The Dan L Duncan Comprehensive Cancer Center to study mitochondrial RNAs in triple negative breast cancer. Congrats!
Congratulations to Dr. Tony Mustoe and colleagues on their recent publication “Mutation signature filtering enables high-fidelity RNA structure probing at all four nucleobases with DMS” in NAR.
Dr. Trey Westbrook and Dr. Elizabeth Bowling were awarded a multi-investigator R01 to investigate how therapeutics targeting RNA splicing can engage the immune system for durable solid tumor responses. Congratulations!
THINC is moving to Helix Park! BCM will be the anchor tenant of One Dynamic in Helix Park and THINC labs will join other highly innovative and therapeutics focused groups from BCM and other TMC institutions in 2024.
upcoming events
Dr. Kate Meyer from Duke University will be presenting our next seminar on Wednesday April 24th, in M112 at 3:00 P.M. We hope you can join us!
The next RNA Group Talk will be on April 29th at 10am in M112. Emily Park of the Bruno Lab and Dr. Paulo Onuchic from the Boeynaems Lab will present their work. See you there!